Contact the Editorial Desk

Editorial correspondence

Peptide Cycles welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial on CJC-1295, ipamorelin, or MOTS-c, a corrected effect size, or a study design detail this desk got wrong. This class of message — one that improves the accuracy of a specific claim on a specific page — is the most useful thing this desk receives, and each one is read carefully.

The most actionable submissions specify: the page in question, the exact claim being corrected, and the supporting source, ideally with a DOI or PubMed identifier. That format allows a proposed correction to be verified against its source before anything on the site changes.

Editorial mailbox: editors@peptidecycles.com

What this desk cannot do

Peptide Cycles is a literature digest, not a clinical service or a product vendor, so it cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a specific study's findings apply to a specific person's situation, or help locate, source, or recommend a supplier for any compound. None of the three compounds covered here is approved for human use anywhere; readers seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.